Trials / Completed
CompletedNCT05314231
Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria
A Phase 1b, Open-Label, Single-Dose Pharmacokinetic Study of Subcutaneous ALXN1720 in Adult Participants With Varying Degrees of Proteinuria
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 19 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess the impact of proteinuria on the pharmacokinetic (PK) of a single dose of ALXN1720 in participants with proteinuria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALXN1720 | All enrolled participants will receive a single dose of ALXN1720 on Day 1 followed by a Post-treatment and Follow-up Period (92 days). |
Timeline
- Start date
- 2022-06-29
- Primary completion
- 2023-05-31
- Completion
- 2023-05-31
- First posted
- 2022-04-06
- Last updated
- 2023-06-29
Locations
2 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05314231. Inclusion in this directory is not an endorsement.